Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director | June 09, 2026 | June 11, 2026 |
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director | January 01, 2024 | January 03, 2024 |
| NAVIDEA BIOPHARMACEUTICALS, INC.NAVB · Entity 107761 | Director | February 20, 2018 | February 22, 2018 |
| Verastem, Inc.VSTM · Entity 5242 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,844 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 1,505 · Balance 25,844 F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.
Fortress Biotech, Inc.
Report date January 01, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.001SEC Table I · non-derivative | Direct | 68,797 |
Reported balance
After 2024-01-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-01 · Grant · Acquired 6,666 · Balance 68,797 F1: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F3: Total holdings include 19,998 shares underlying deferred restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split.
F2: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer.
F3: Total holdings include 19,998 shares underlying deferred restricted stock units.
NAVIDEA BIOPHARMACEUTICALS, INC.
Report date February 20, 2018 · Filed February 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 341,446 |
Reported balance
After 2018-02-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-20 · Grant · Acquired 50,000 · Balance 341,446 F1: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2028-02-20 | Direct | 173,764 |
Reported balance
After 2018-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-20 · Grant · Acquired 50,000 · Balance 173,764 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant.
Verastem, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,666 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 36,000 · Balance 52,666 F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 21:46 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,505 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000063 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,844 F1 · shares: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. Read SEC document |
| May 21, 2026 Filed May 26, 2026 22:21 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-066422 · tm2615478-5_4seq1.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,666 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:44 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 2,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017760 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,339 Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:40 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001104659-25-053092 · tm2516118-1_4seq1.xml · derivative · entry 2 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:40 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-053092 · tm2516118-1_4seq1.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-019238 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,969 Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:32 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001104659-24-073610 · tm2417704-6_4seq1.xml · derivative · entry 2 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-18 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:32 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073610 · tm2417704-6_4seq1.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 F1 · shares: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:16 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,572 | Not disclosed Strike: $11.44 | Not disclosed |
DisclosureSEC source: 0001104659-24-034043 · tm248737-6_4seq1.xml · derivative · entry 6 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,572 Underlying: Common Stock · 12,572 shares Expires 2034-03-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F1 · derivative.exercise_date: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:16 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 2,083 | Not disclosed Strike: $49.92 | Not disclosed |
DisclosureSEC source: 0001104659-24-034043 · tm248737-6_4seq1.xml · derivative · entry 5 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2031-06-28 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F6 · derivative.exercise_date: The canceled stock option was granted on June 28, 2021 and provided for vesting in twelve equal month installments beginning on the on the last day of each month over a period from June 2021 to May 2022. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:16 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 2,083 | Not disclosed Strike: $21.24 | Not disclosed |
DisclosureSEC source: 0001104659-24-034043 · tm248737-6_4seq1.xml · derivative · entry 4 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2030-06-16 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F5 · derivative.exercise_date: The canceled stock option was granted on June 16, 2020 and provided for vesting in twelve equal monthly installments beginning on June 30, 2020 and ending on May 31, 2021. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:16 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 2,083 | Not disclosed Strike: $21.72 | Not disclosed |
DisclosureSEC source: 0001104659-24-034043 · tm248737-6_4seq1.xml · derivative · entry 3 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2029-06-21 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F4 · derivative.exercise_date: The canceled stock option was granted on June 21, 2019 and provided for vesting in twelve equal monthly installments beginning on July 21, 2019 and ending on June 21, 2020. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:16 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 2,157 | Not disclosed Strike: $67.08 | Not disclosed |
DisclosureSEC source: 0001104659-24-034043 · tm248737-6_4seq1.xml · derivative · entry 2 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,157 shares Expires 2028-06-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F3 · derivative.exercise_date: The canceled stock option was granted on June 21, 2018 and provided for vesting in twelve equal monthly installments beginning on July 11, 2018 ending on June 11, 2019. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:16 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 4,166 | Not disclosed Strike: $25.08 | Not disclosed |
DisclosureSEC source: 0001104659-24-034043 · tm248737-6_4seq1.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2027-06-13 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F2 · derivative.exercise_date: The canceled stock option was granted on June 13, 2017 and provided for vesting in twelve monthly installments through June 13, 2018, with the first monthly installment vesting on July 13, 2017. Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 02:13 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 455 | $222.54 | $101,255.70 |
DisclosureSEC source: 0001127602-24-005922 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,629 Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:47 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000899 · tm241755-11_4seq1.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,797 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F3 · balance_after: Total holdings include 19,998 shares underlying deferred restricted stock units. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 23:06 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 960 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019547 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,174 Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:35 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-23-061427 · tm2315836-8_4seq1.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-05-15 F1 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2023 to April, 2024 and the last installment shall vest on the earlier of (i) the day before the 2024 Annual Meeting of Stockholders is held or (ii) May 31, 2024, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:11 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 11,976 | $0.84 | $9,999.96 |
DisclosureSEC source: 0001104659-23-021625 · tm236803-5_4seq1.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 931,976 F1 · balance_after: The total holdings include 200,000 shares of deferred restricted stock. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 02:26 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001100 · tm231728-6_4seq1.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,000 F1 · shares: One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer. F2 · balance_after: The total holdings include 200,000 shares of deferred restricted stock. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:09 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-074304 · tm2219034-9_4seq1.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-06-22 F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017808 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,214 Read SEC document |
| May 12, 2022 Filed Dec 20, 2022 21:06 UTC Amendment | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001104659-22-128630 · tm2232937-3_4aseq1.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-05-12 F1 · security: On June 24, 2022 the Reporting Person filed a Form 4 reporting a stock option grant which incorrectly stated an exercise price of $1.11, a transaction date of June 22, 2022 and an expiration date of June 22, 2032. This amendment is being filed to reflect the corrected exercise price of $1.07, transaction date of May 12, 2022 and expiration date of May 12, 2032. F2 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| January 01, 2022 Filed Apr 29, 2022 20:16 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053572 · tm2213913-2_4seq1.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,000 F1 · shares: One-third of the shares will vest on each January 1, 2023, 2024 and 2025, subject to continued service. F2 · balance_after: The total holdings include 100,000 shares of deferred restricted stock. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:32 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021346 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,844 Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:58 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001104659-21-087401 · tm2121071-3_4seq1.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| March 02, 2021 Filed Apr 9, 2021 21:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 10,000 | $4.45 | $44,500.00 |
DisclosureSEC source: 0001104659-21-048831 · tm219139d7_4.xml · nonDerivative · entry 6 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,000 F2 · shares: In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations. F7 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 2, 2021, was $4.40 to $4.50.* Read SEC document |
| February 19, 2021 Filed Apr 9, 2021 21:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 8,000 | $4.31 | $34,480.00 |
DisclosureSEC source: 0001104659-21-048831 · tm219139d7_4.xml · nonDerivative · entry 5 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,000 F2 · shares: In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations. F6 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 19, 2021, was $4.30 to $4.31.* Read SEC document |
| February 18, 2021 Filed Apr 9, 2021 21:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 6,000 | $4.20 | $25,200.00 |
DisclosureSEC source: 0001104659-21-048831 · tm219139d7_4.xml · nonDerivative · entry 4 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,000 F2 · shares: In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations. F5 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 18, 2021, was $4.19 to $4.23.* Read SEC document |
| February 16, 2021 Filed Apr 9, 2021 21:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 2,000 | $3.86 | $7,720.00 |
DisclosureSEC source: 0001104659-21-048831 · tm219139d7_4.xml · nonDerivative · entry 3 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,000 F2 · shares: In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations. F4 · price: Reflects an open market sale transaction effected by the Reporting Person through a sale order executed by a broker-dealer.* Read SEC document |
| February 05, 2021 Filed Apr 9, 2021 21:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 4,000 | $3.80 | $15,200.00 |
DisclosureSEC source: 0001104659-21-048831 · tm219139d7_4.xml · nonDerivative · entry 2 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,000 F2 · shares: In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations. F3 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 5, 2021, was $3.75 to $3.84.* Read SEC document |
| January 01, 2021 Filed Apr 9, 2021 21:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048831 · tm219139d7_4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 F1 · shares: Annual grant of restricted shares of Issuer stock to members of the Issuer's Board of Directors. One-third of the shares will vest on each January 1, 2022, 2023 and 2024, subject to continued service. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:04 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000904454-20-000409 · edgar.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on June 30, 2020 and ending on May 31, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:23 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019032 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,069 Read SEC document |
| January 01, 2020 Filed Mar 13, 2020 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-033117 · tm2011481-7_form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 F1 · shares: One-third of the shares will vest on each of January 1, 2021, 2022, and 2023, subject to continued service. Read SEC document |
| June 21, 2019 Filed Jun 26, 2019 01:38 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001104659-19-037499 · a4.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-21 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/21/2019 and ending on 06/21/2020, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022427 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,179 Read SEC document |
| January 01, 2019 Filed Apr 12, 2019 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019493 · tv516216_4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 F1 · shares: One-third of the shares will vest on each of January 1, 2020, 2021, and 2022, subject to continued service. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:25 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020945 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,024 Read SEC document |
| June 11, 2018 Filed Feb 13, 2019 21:44 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,891 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000904454-19-000221 · edgar.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,891 Underlying: Common Stock · 25,891 shares Expires 2028-06-11 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/11/2018 and ending on 06/11/2019, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:40 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.75 | $50.00 |
DisclosureSEC source: 0001437749-18-003139 · rdgdoc.xml · derivative · entry 2 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,764 Underlying: Common Stock · 50,000 shares Expires 2028-02-20 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:40 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001437749-18-003139 · rdgdoc.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,446 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
| January 01, 2018 Filed Nov 30, 2018 22:27 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062676 · tv495942_4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 F1 · shares: One-third of the shares will vest on each of January 1, 2019, 2020, and 2021, subject to continued service. Read SEC document |
| September 05, 2017 Filed Jan 24, 2024 21:00 UTC | Verastem, Inc. VSTM · Entity 5242 | PurchaseCommon Stock | 2,000 | $3.84 | $7,680.00 |
DisclosureSEC source: 0001104659-24-006241 · tm244024-1_4seq1.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 2,000 F1 · ownership.nature: In connection with recent divorce proceedings, Dr. Rowinsky learned of the purchase of Verastem, Inc. securities by his spouse, Lisa Slater, on September 5, 2017. Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 16:35 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.75 | $50.00 |
DisclosureSEC source: 0001437749-17-012100 · rdgdoc.xml · derivative · entry 2 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-30 Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 16:35 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001437749-17-012100 · rdgdoc.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,446 F1 · shares: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:20 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001104659-17-039557 · a4.xml · derivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: This option will vest in twelve monthly installments through June 13, 2018, with the first monthly installment vesting on July 13, 2017. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-021106 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,144 F1 · balance_after: On 6/8/16 an RSU was awarded for 1,060 shares. This award was adjusted to 1,084 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| January 01, 2017 Filed Jan 25, 2017 00:02 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000109 · doc4_4421.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 F1 · shares: One-third of the shares will vest on each of January 1, 2018, 2019 and 2020, and subject to continued service on the board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.